The European Union's (EU) drug regulator has rejected Eisai and Biogen's (NASDAQ: BIIB) Leqembi treatment for early Alzheimer's disease, citing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE